Table 1

The correlation between HER2 expression status and clinicopathological parameters
Overall HER2 HER2- HER2-
Overexpression Equivocal Negative Pvalue
Pathologic feature n=1463 n=143 (%) n=211 (%) n=1109 (%)
Age at diagnosis 0.102
≥60 years 683 80 (11.7) 108 (15.8) 495 (72.5)
<60 years 780 63 (8.1) 103 (13.2) 614 (78.7)
Sex 0.344
Male 1104 109 (9.9) 171 (15.5) 824 (74.6)
Female 359 34 (9.5) 40 (11.1) 285 (79.4)
Tumor location 0.003
GC 929 65 (7.0) 121 (13.0) 743 (80.0)
GEJ 534 78 (14.6) 90 (16.9) 366 (68.5)
Tumor subtype
(Lauren classification) 0.000
 Intestinal 650 109 (16.8) 111 (17.1) 430 (66.2)
 Diffuse 564 13 (2.3) 63 (11.2) 488 (86.5)
 Mixed 249 21 (8.4) 37 (14.9) 191 (76.7)
Tumor differentiation 0.000
 Well 25 4 (16) 9 (36) 12 (48)
 Moderately 369 74 (20.1) 70 (19.0) 225 (61.0)
 Poorly 1069 65 (6.1) 132 (12.3) 872 (81.6)
pT status 0.053
 pT1 206 16 (7.8) 33 (16.0) 157 (76.2)
 pT2 147 23 (15.6) 28 (19.0) 96 (65.3)
 pT3 1074 102 (9.5) 145 (13.5) 827 (77.0)
 pT4 36 2 (5.6) 5 (13.9) 29 (80.6)
pN status 0.074
 pN0 411 39 (9.5) 66 (16.1) 306 (74.5)
 pN1 235 27 (11.5) 42 (17.9) 166 (70.6)
 pN2 306 20 (6.5) 42 (13.7) 244 (79.7)
 pN3 511 57 (11.2) 61 (11.9) 393 (76.9)
pM status 0.571
 pM0 1429 140 (9.8) 119 (8.3) 1080 (75.6)
 pM1 34 3 (8.8) 2 (5.9) 29 (85.3)
pTNM stages 0.327
 IA 162 14 (8.6) 29 (17.9) 119 (73.5)
 IB 93 8 (8.6) 17 (18.3) 68 (73.1)
 IIA 201 25 (12.4) 33 (16.4) 143 (71.1)
 IIB 230 25 (10.9) 34 (14.8) 171 (74.3)
 IIIA 264 15 (5.7) 37 (14.8) 212 (80.3)
 IIIB 455 51 (11.2) 56 (12.3) 348 (76.5)
 IIIC 24 2 (8.3) 3 (12.5) 19 (79.2)
 IV 34 3 (8.8) 2 (5.9) 29 (85.3)

Shan et al.

Shan et al. Diagnostic Pathology 2013 8:76   doi:10.1186/1746-1596-8-76

Open Data